BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 14742769)

  • 21. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
    Hashimoto Y; Wakayama N; Miyauchi A
    Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide.
    Eastell R; Krege JH; Chen P; Glass EV; Reginster JY
    Curr Med Res Opin; 2006 Jan; 22(1):61-6. PubMed ID: 16393431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Teriparatide: human recombinant parathyroid hormone (1-34) as a daily subcutaneous injection].
    Sowa H; Hamaya E; Yamamoto T
    Clin Calcium; 2011 Jan; 21(1):9-16. PubMed ID: 21187589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Teriparatide: A bone formation treatment for osteoporosis.
    Eriksen EF; Robins DA
    Drugs Today (Barc); 2004 Nov; 40(11):935-48. PubMed ID: 15645006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial experience with teriparatide in the United States.
    Gold DT; Pantos BS; Masica DN; Misurski DA; Marcus R
    Curr Med Res Opin; 2006 Apr; 22(4):703-8. PubMed ID: 16684431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice.
    Lim LS; Hoeksema LJ; Sherin K;
    Am J Prev Med; 2009 Apr; 36(4):366-75. PubMed ID: 19285200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic prevention of osteoporotic fractures.
    Zizic TM
    Am Fam Physician; 2004 Oct; 70(7):1293-300. PubMed ID: 15508540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes of the quality-of-life under the treatment of severe senile osteoporosis with teriparatide.
    Maugeri D; Russo E; Luca S; Leotta C; Mamazza G; Sorace R; Rizzotto M; Manuele S; Fiore V; Taverna G; Castiglia B; Calitro M
    Arch Gerontol Geriatr; 2009; 49(1):35-8. PubMed ID: 18555544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
    Anastasilakis AD; Polyzos SA; Avramidis A; Papatheodorou A; Terpos E
    Horm Metab Res; 2009 Jul; 41(7):559-62. PubMed ID: 19204890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment with recombinant parathyroid hormone of advanced osteoporosis--series of cases].
    Skiba K; Adamczak M; Wiecek A
    Przegl Lek; 2011; 68(7):391-5. PubMed ID: 22010479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Parathyroid hormone for osteroporsis: why and who to treat?].
    Ferrari S; Rizzoli R
    Rev Med Suisse; 2005 Oct; 1(35):2272-4, 2276-7. PubMed ID: 16268450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Teriparatide: a review.
    Quattrocchi E; Kourlas H
    Clin Ther; 2004 Jun; 26(6):841-54. PubMed ID: 15262455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide.
    Crans GG; Silverman SL; Genant HK; Glass EV; Krege JH
    Arthritis Rheum; 2004 Dec; 50(12):4028-34. PubMed ID: 15593198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Teriparatide in the treatment of osteoporosis.
    Stroup J; Kane MP; Abu-Baker AM
    Am J Health Syst Pharm; 2008 Mar; 65(6):532-9. PubMed ID: 18319498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.
    Hodsman AB; Bauer DC; Dempster DW; Dian L; Hanley DA; Harris ST; Kendler DL; McClung MR; Miller PD; Olszynski WP; Orwoll E; Yuen CK
    Endocr Rev; 2005 Aug; 26(5):688-703. PubMed ID: 15769903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapeutic effect of recombinant human parathyroid hormone(1-34) on osteoporosis of ovariectomized rats].
    Wang HF; Jin WF; Gao JJ; Gu SZ; Zhou Y; Sun AL; Hu F; Shen J; Zhang SC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Jun; 25(3):275-9. PubMed ID: 12905739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Spotlight on teriparatide in osteoporosis.
    Blick SK; Dhillon S; Keam SJ
    BioDrugs; 2009; 23(3):197-9. PubMed ID: 19627171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of teriparatide and its clinical efficacy in the treatment of osteoporosis.
    Dobnig H
    Expert Opin Pharmacother; 2004 May; 5(5):1153-62. PubMed ID: 15155114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapeutic agents for disorders of bone and calcium metabolism: Weekly subcutaneous injection of teriparatide.].
    Ishizuya T
    Clin Calcium; 2011 Jan; 21(1):17-24. PubMed ID: 21187590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.